Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ECS Botanics HoldingsASX:ECS +20.00% Revenue per Share is A$0.02 as of Jun. 2026. The stock has 7 warning signs investors should review. Among 905 Drug Manufacturers companies, ECS Botanics Holdings ranks worse than 110497.13% on this metric.
ECS Botanics Holdings's revenue per share for the
six
months ended in Jun. 2026 was A$0.01.
ECS Botanics Holdings's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.02.
Warning Sign:
ECS Botanics Holdings Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of ECS Botanics Holdings was -6.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 41.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for ECS Botanics Holdings's Revenue per Share or its related term are showing as below:
During the past 13 years, ECS Botanics Holdings's highest 3-Year average Revenue Per Share Growth Rate was 286.40% per year. The lowest was -95.00% per year. And the median was 0.00% per year.
ASX:ECS's 3-Year Revenue Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ECS Botanics Holdings Revenue per Share Related Terms
ECS Botanics Holdings Revenue per Share Historical Data
* Premium members only.
The historical data trend for ECS Botanics Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ECS Botanics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ECS Botanics Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ECS Botanics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where ECS Botanics Holdings's PS Ratio falls into.
ECS Botanics Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
ECS Botanics Holdings's Revenue Per Share for the fiscal year that ended in Jun. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECS Botanics Holdings (ASX:ECS) has a Revenue per Share of A$0.02 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on ECS Botanics Holdings and its competitors. According to the industry distribution chart, ECS Botanics Holdings ranks #999999 out of 905 companies in the Drug Manufacturers industry.
Is ECS Botanics Holdings' Revenue per Share too high?
ECS Botanics Holdings' current Revenue per Share is A$0.02. Based on the distribution chart, ECS Botanics Holdings ranks #999999 out of 905 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does ECS Botanics Holdings' Revenue per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ECS Botanics Holdings ranks #999999 out of 905 companies for Revenue per Share. This places ECS Botanics Holdings in the lower half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on ECS Botanics Holdings and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ECS Botanics Holdings's current Revenue per Share is A$0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
ECS Botanics Holdings (ASX:ECS) has a current Revenue per Share of A$0.02. The current Revenue per Share is A$0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current Revenue per Share is A$0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ECS has been successfully added to your 
